Skip to main content
OpenTrials
Completed

NCT Number: NCT01792999

Koning Breast CT for Breast Imaging in China

This study is conducted to compare Koning Breast CT (KBCT) to mammography to evaluate if KBCT can improve the diagnostic accuracy of breast cancer. It will also compare contrast-enhanced KBCT (CE-KBCT) to mammography to evaluate if CE-KBCT can further improve the diagnostic accuracy of breast cancer.

Completed

Looking for future studies?

Notify Me

Key information

Age range

35 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Non-contrast KBCT

Inclusion criteria

  • Females at least 35 years of age of any ethnicity
  • Had diagnostic imaging
  • Will undergo study imaging no later than two weeks from date of diagnostic mammogram
  • Is able to undergo informed consent

Exclusion criteria

  • Pregnancy
  • Lactation
  • Subjects with physical limitations that may prohibit resting prone on the exam table, such as, but not limited to: frozen shoulder, recent heart surgery, pace maker.
  • Subjects who are unable to tolerate study constraints.
  • Subjects who have received radiation treatments to the thorax for malignant and nonmalignant conditions, such as (but not limited to)
  • Treatment for enlarged thymus gland as an infant
  • Irradiation for benign breast conditions, including breast inflammation after giving birth
  • Treatment for Hodgkins disease
  • Subjects who have participated in a prior breast clinical trial that gave additional radiation dose, such as an additional mammogram.
  • Subjects who have received large numbers of diagnostic x-ray examinations for monitoring of disease such as (but not limited to)
  • Tuberculosis
  • Severe scoliosis

Contrast-enhanced KBCT

Inclusion criteria

  • Females at least 35 years of age of any ethnicity
  • Had diagnostic imaging and was determined to have biopsy or surgery
  • Will undergo study imaging no later than two weeks from date of diagnostic mammogram
  • Is able to undergo informed consent

Exclusion criteria

Same as the exclusion criteria as non-contrast KBCT, plus the following:

  • Abnormal Glomerular Filtration Rate (GFR)/Blood Urea Nitrogen (BUN) or Creatinine at Pre contrast blood screening
  • Previous non-ionic contrast reaction
  • History of renal dysfunction/kidney disease
  • Diabetes mellitus treated with metformin
  • Multiple myeloma
  • Dehydration
  • History of nephrotoxic medication use
  • Hyperthyroidism
  • Pheochromocytoma
  • Sickle Cell Disease

Treatment and study plan

Contrast-enhanced KBCT

Device

Contrast-enhanced KBCT includes pre-contrast KBCT scan and post-contrast KBCT scan. After the pre contrast scan is completed, a bolus injection of a low osmolar, nonionic, iodinated 300mg of iodine per mL contrast agent, will be injected at a rate of approximately 2.0 mL/s, for a total injection time of approximately 30-60 seconds. 30-60 seconds after the contrast injection, the post-contrast scan will be acquired.

Primary outcomes

  1. Efficacy of KBCT, CE-KBCT and Mammography

    Time frame: 1 year

    Efficacy of KBCT, CE-KBCT and Mammography will be assessed based on the sensitivity for detecting breast cancer and the specificity for correctly categorizing non-cancer.

Secondary outcomes

  1. Safety of KBCT, CE-KBCT and Mammography

    Time frame: 1 year

    All enrolled and scanned patients will be included in the safety analysis. Anticipated and unanticipated adverse events will be tabulated according to severity and relation to device.

Sponsors and collaborators

Lead sponsor

Koning (Tianjin) Medical Equipment Co., Ltd

Industry

Registry information

Important dates

Study start
2012
Primary completion
2014
Study completion
2014
First posted
Feb 15, 2013
Registry last updated
Mar 7, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.